Vincent Hsu
Infectious Disease · Orlando, FLNPI 1255331146
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $144,015 of the $221,798 with a category attached, or 64.9%. Merck accounts for 61.3% of it on its own, with 14 other manufacturers making up the rest. 2025 is the largest year on record at $62,201, 2.5 times the $24,986 reported in 2019. Among infectious disease clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 242 payments — averaging $916.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$136K
- Sanofi Pasteur Inc.$46K
- Pfizer$18K
- Valneva USA, Inc.$14K
- Gilead$7K
- AstraZeneca$209
- plus $643 from 9 others
What the payments were for
- Consulting fees$47,45921%
- Speaking & faculty fees$144,01565%
- Travel & lodging$25,10711%
- Food & beverage$5,2172%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 121 | $136,059 |
| Sanofi Pasteur Inc. | 52 | $46,429 |
| Pfizer | 21 | $17,692 |
| Valneva USA, Inc. | 20 | $13,655 |
| Gilead | 17 | $7,112 |
| AstraZeneca | 2 | $209 |
| AbbVie | 1 | $125 |
| Viiv Healthcare Company | 1 | $125 |
| Boehringer Ingelheim | 1 | $122 |
| Insmed, Inc. | 1 | $119 |
| Accelerate Diagnostics Inc. | 1 | $49 |
| Janssen Scientific Affairs, LLC | 1 | $31 |
| Shionogi Inc | 1 | $26 |
| GSK | 1 | $23 |
| Beckman Coulter, Inc. | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAPVAXIVE$71,806
- FLUZONE HIGH-DOSE$33,291
- PNEUMOVAX 23$26,534
- FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE$15,996
- VAXNEUVANCE$10,971
- PENBRAYA$9,872
- FLUBLOK QUADRIVALENT$8,582
- FLUZONE QUADRIVALENT$6,199
- MENQUADFI$5,524
- DISEASE STATE$2,858
- PREVNAR 20$2,200
- ABRYSVO$2,000
- IXCHIQ$2,000
- Veklury$1,260
- FLUZONE QUADRIVALENT NORTHERN HEMISPHERE$499
- STRATTICE$125
- LOKELMA$125
- RUKOBIA$125
- Biktarvy$125
- Epclusa$122
How this compares
$221,798 in reported general payments places this provider in the 95th percentile of 669 infectious disease providers in Florida.
Other infectious disease in Orlando
- Charlotte-Paige RolleOrlando$619K
- Kenneth AlexanderOrlando$474K
- Federico HinestrosaOrlando$276K
- Erick SuarezOrlando$114K
- Roberto OrtizOrlando$71K
- Edwin DejesusOrlando$42K
- Patricia CoutoOrlando$28K
- Lennox ArchibaldGainesville$2.1M
- Moti RamgopalFort Pierce$1.1M
- Juan DiazAltamonte Springs$980K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.